Soleus Capital Special Opportunities Fund, L.P. 13D and 13G filings for ESSA Pharma Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-11 4:00 pm Sale | 2024-12-31 | 13G | ESSA Pharma Inc. EPIX | Soleus Capital Special Opportunities Fund, L.P. | 2,262,026 5.100% | -2,065,596 (-47.73%) | Filing |
| 2024-01-23 4:09 pm Purchase | 2023-12-31 | 13G | ESSA Pharma Inc. EPIX | Soleus Capital Special Opportunities Fund, L.P. | 4,327,622 9.800% | 458,230 (+11.84%) | Filing |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | ESSA Pharma Inc. EPIX | Soleus Capital Special Opportunities Fund, L.P. | 3,869,392 8.800% | 3,869,392 (New Position) | Filing |